Abstract:Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system adapted from bacteria is a programmable nuclease-based genome editing tool. The long-lasting effect of gene silencing or correction is beneficial in cancer treatment. Considering the need to broaden the practical application of this technology, highly efficient non-viral vectors are urgently required. We prepared a multifunctional non-viral vector that could actively target tumor cells and deliver CRISPR/Cas9 plasmids into nuclei of cancer cells. Protamine sulfate (PS) which contains nuclear localization sequence was utilized to condense plasmid DNA and facilitate nuclei-targeted delivery. Liposome-coated protein/DNA complex avoided the degradation of nuclease in blood circulation. The obtained /pCas9 was further modified with distearoyl phosphoethanolamine-polyethylene glycol-hyaluronic acid (HA) to endow the vector ability to actively target tumor cell. Results suggested that could deliver CRISPR/Cas9 plasmids into nuclei of tumor cells and induce genome editing effect. With the disruption of MTH1 (mutT homolog1) gene, the growth of non-small cell lung cancer was inhibited. Moreover, cell apoptosis in tumor tissue was promoted, and liver metastasis of non-small cell lung cancer (NSCLC) was reduced. Our study has provided a therapeutic strategy targeting MTH1 gene for NSCLC therapy. Statement of significance CRISPR/Cas9 as a powerful tool for genome editing has drawn much attention. The long-lasting effect possesses unique advantage in cancer treatment. Non-viral vectors have high loading capacity, high safety and low immunogenicity, playing an important role in CRISPR/Cas9 delivery. In our study, a multifunctional non-viral vector for the efficient delivery of CRISPR/Cas9 plasmid was constructed. With the active targeting ligand and nuclei-targeting component, the cargo was efficiently delivered into cell nuclei and exerted genome editing effect. By using this vector, we successfully inhibited the growth and induced the apoptosis of non-small cell lung cancer by disrupting MTH1 expression with good safety. Our work provided an efficient non-vial vector for CRISPR/Cas9 delivery and explored the possibility for cancer treatment.

Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours

Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control

Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells.

In Vivo Gene Editing of T-cells in Lymph Nodes for Enhanced Cancer Immunotherapy

Sono‐Controllable and ROS‐Sensitive CRISPR‐Cas9 Genome Editing for Augmented/Synergistic Ultrasound Tumor Nanotherapy

Magnetothermal-activated gene editing strategy for enhanced tumor cell apoptosis

Hypoxia-Responsive Gene Editing to Reduce Tumor Thermal Tolerance for Mild-Photothermal Therapy.

Controlled CRISPR‐Cas9 Ribonucleoprotein Delivery for Sensitized Photothermal Therapy (Small 33/2021)

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Highly Efficient Homology-Driven Genome Editing in Human T Cells by Combining Zinc-Finger Nuclease Mrna and AAV6 Donor Delivery.

Control of the activity of CAR-T cells within tumours via focused ultrasound

Gene-activating Nanomedicine for the Tumor-Oriented Infiltration of T Cells to Enhance Immunotherapy Against Solid Tumors

Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy

Targeting Genomic Rearrangements in Tumor Cells Through Cas9-mediated Insertion of a Suicide Gene

Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy

Time-programmed activation of CD47 disruption and immunogenic cell death with Cas9 ribonucleoprotein nanocapsule for improved cancer immunotherapy

Antigen-specific T Cell Activation Through Targeted Delivery of In-Situ Generated Antigen and Calcium Ionophore to Enhance Antitumor Immunotherapy.

A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy

Dual‐Responsive Turn‐on T1 Imaging‐Guided Mild Photothermia for Precise Apoptotic Cancer Therapy

Gene editing of gene to redirect regulatory T cells for adoptive T cell transfer